New drug combo shows promise in shrinking liver tumors before surgery
NCT ID NCT05807776
First seen Apr 04, 2026 · Last updated Jun 13, 2026 · Updated 11 times
Summary
This study tested giving the drugs tislelizumab (alone or with lenvatinib) before surgery for liver cancer that can be removed. The goal was to see if this pre-surgery treatment could shrink tumors and improve outcomes. 36 adults with liver cancer took part. The main measure was how much the tumor died after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.